Introduction
============

Hepatocellular carcinoma (HCC) is a prevalent malignant liver disease ([@b1-ol-0-0-11470]). In most cases, viral infection contributes to the development, invasion and metastasis of HCC ([@b2-ol-0-0-11470]), which is a global public health problem. In particular, chronic hepatitis B virus (HBV) is one of the leading causes of HCC with an estimated 400 million individuals currently affected by chronic infection worldwide ([@b3-ol-0-0-11470],[@b4-ol-0-0-11470]). More than 50% of HCC cases arise from chronic HBV infections ([@b5-ol-0-0-11470],[@b6-ol-0-0-11470]). In high-prevalence areas, chronic HBV infection is estimated to account for over 80% of HCC cases ([@b7-ol-0-0-11470]). Moreover, patients with HBV-associated HCC have notably higher rates of metastasis and recurrence compared with those without HBV infection ([@b8-ol-0-0-11470],[@b9-ol-0-0-11470]). Three-quarters of the world\'s population live in areas where there are high levels of HBV infection ([@b10-ol-0-0-11470]). However, the currently available antiviral agents can barely eliminate chronic HBV infection ([@b11-ol-0-0-11470]). HBV-associated liver diseases cause approximately 1 million deaths per year ([@b3-ol-0-0-11470]), driving an intensive search for curative treatment approaches ([@b12-ol-0-0-11470]). Han *et al* ([@b13-ol-0-0-11470]) reported that WNT family gene expression is associated with the development of HBV-associated HCC. Tian and Ou\'s study ([@b14-ol-0-0-11470]) found that chronic HBV infection could lead to chronic inflammation in the liver, which could cause normal liver cells to transform into cancer cells ([@b15-ol-0-0-11470]). Although the correlation between chronic HBV infection and HCC development is strong, the precise molecular mechanisms by which HBV contributes to HCC development are not fully understood ([@b16-ol-0-0-11470]). Therefore, a clearer understanding of the molecular mechanisms of the transformation of nontumor hepatic tissues into HCC tissues in patients with HBV infection is required to guide the treatment of HBV-associated HCC ([@b17-ol-0-0-11470]).

A large array of data could be analyzed, given the remarkable development of high-throughput technologies for the profiling of genome-wide methylation and expression, such as methylation microarray and MeDip-seq, and RNA-seq, and the datasets publicly available worldwide ([@b18-ol-0-0-11470]). Potential biomarkers and signaling pathway associated with tumor regression could be identified using bioinformatics methods.

Thus far, there are insufficient bioinformatics studies focusing on the differentially expressed genes (DEGs) between HCC tissues and nontumor tissues from HBV-infected patients based on a large sample size. In the present study, data from more datasets on the same platform were collected in order to increase the sample size. Using a large cohort, DEGs between HCC tissues and nontumor tissues were identified. Furthermore, Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the DEGs were performed. In addition, protein-protein interaction (PPI) networks were constructed based on the most enriched pathways. The results of the present study may help to identify key biomarkers for the personalized treatment of patients with HCC and a history of HBV infection, and provide further insights into tumor progression and further studies on HCC.

Materials and methods
=====================

### Microarray datasets for differential expression analyses

A comprehensive search was conducted for HCC microarray datasets, including tissue samples from HBV-infected patients in the Gene Expression Omnibus (GEO) database of the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/geo/>) website. All the data of the selected datasets \[GSE17548 ([@b19-ol-0-0-11470]), GSE55092 ([@b20-ol-0-0-11470]), GSE62232 ([@b21-ol-0-0-11470]), GSE84044 ([@b22-ol-0-0-11470]) and GSE84402 ([@b23-ol-0-0-11470])\] were produced from the GPL570 platform. Subsequently, the raw intensity files (CEL) of the datasets were downloaded from the GEO database. The robust multiarray average method of the R package 'affy' (version 1.60.0; <http://bioconductor.org/packages/affy/>) was used to process the raw intensity files and generate a large gene expression matrix of all the selected samples from the datasets meeting the criteria (HBV positive liver tissue samples with status information) for differential expression analyses ([@b24-ol-0-0-11470]). The matrices for each selected dataset were also generated. In addition, we used two independent HCC datasets, The Cancer Genome Atlas (TCGA; <http://portal.gdc.cancer.gov/projects/TCGA-LIHC>) and GSE76427 ([@b25-ol-0-0-11470]), including HCC patients without HBV infection to further elucidate the specificity of the expression of target genes in HBV-associated HCC.

### Analyses of DEGs

Within the large cohort, the DEGs between HCC tissues and nontumor hepatic tissues were identified using the R package 'limma' (version 3.38.3; <http://bioconductor.org/packages/limma/>), which is based on unpaired t-test ([@b26-ol-0-0-11470]); with the thresholds of log~2~-fold change \>1 or \<-1 and adjusted P-value \<0.05. The results of the differential expression analyses were visualized with a volcano plot using the R package 'ggplot2' (version 3.1.0; <http://bioconductor.org/packages/ggplot2/>). The top 50 upregulated and top 50 downregulated DEGs were represented by heatmaps using the MeV software (version 4.9.0; <http://mev.tm4.org/>) in the selected datasets. The unsupervised hierarchical clustering of the selected genes and samples in the heatmaps was performed using an average linkage method using Pearson\'s correlation.

### Enrichment analysis of GO function and KEGG pathway

GO (<http://www.geneontology.org>) function and KEGG (<https://www.kegg.jp/>) pathways enrichment analyses of the upregulated and downregulated DEGs were performed using the WEB-based GEne SeT AnaLysis Toolkit (<http://www.webgestalt.org/>) via a significance threshold of false discovery rate (FDR) \<0.05, in order to understand the critical biological implications of the identified DEGs in HBV-positive HCC tissues.

### PPI network analyses

To further understand the direct and indirect associations among the DEGs, PPI networks of the upregulated and downregulated DEGs based on the top pathways of the KEGG pathway enrichment analysis were constructed and visualized using the Search Tool for the Retrieval of Interacting Genes/Proteins (<https://string-db.org>) database. The aforementioned methods are summarized in [Fig. 1](#f1-ol-0-0-11470){ref-type="fig"}.

Results
=======

### Selection of microarray datasets for differential expression analysis

From the GEO database of NCBI, five datasets (GSE17548, GSE55092, GSE62232, GSE84044 and GSE84402) that met the study criteria were used for differential expression analyses. Within the five datasets, 321 HBV-positive samples with valid hepatic tissue status were selected to generate the gene expression matrix; 82 of which were tumor tissues, and 239 of which were nontumor tissues ([Table I](#tI-ol-0-0-11470){ref-type="table"}). The clinical characteristics of enrolled subjects can be found in supplementary data ([Table SI](#SD1-ol-0-0-11470){ref-type="supplementary-material"}).

### DEGs in HCC tissues compared with nontumor hepatic tissues

The expression values of 42,901 genes among 82 HCC samples were compared with 239 nontumor hepatic samples from five GEO datasets. A total of 1934 DEGs were identified with the thresholds of fold change \>1 or \<-1 and adjusted P-value \<0.05, including 682 upregulated genes and 1,252 downregulated genes. All DEGs are marked as red dots in the volcano plot ([Fig. 2](#f2-ol-0-0-11470){ref-type="fig"}). In addition, the top 50 upregulated genes and downregulated genes are listed in [Tables II](#tII-ol-0-0-11470){ref-type="table"} and [III](#tIII-ol-0-0-11470){ref-type="table"}, respectively (the top 100 up- and downregulated genes are listed in [Tables SII](#SD1-ol-0-0-11470){ref-type="supplementary-material"} and [SIII](#SD1-ol-0-0-11470){ref-type="supplementary-material"}, respectively). The heat maps of GSE17548, GSE55092 and GSE84402 demonstrate the expression of the top 100 DEGs (50 upregulated and 50 downregulated) in different subsets (GSE17548 and GSE84402 in [Fig. 3](#f3-ol-0-0-11470){ref-type="fig"}; GSE55092 in [Fig. S1](#SD1-ol-0-0-11470){ref-type="supplementary-material"}).

### GO functional and KEGG pathway enrichment analyses of the upregulated and downregulated DEGs

In order to understand the biological implications of the identified DEGs in HBV-positive HCC tissues, GO functional and KEGG pathway enrichment analyses of the identified DEGs were performed. The GO terms of the up- and downregulated DEGs are presented in [Fig. 4](#f4-ol-0-0-11470){ref-type="fig"}.

In the GO biological process category, upregulated DEGs were closely associated with the 'biological regulation' and 'metabolic process' terms, whereas the downregulated DEGs were closely associated with the 'metabolic process' and 'biological regulation' terms.

In the GO cellular component category, upregulated DEGs were closely associated with the 'nucleus' and 'membrane' terms, whereas the downregulated DEGs were closely associated with the 'membrane' and 'vesicle' terms.

In the GO molecular category, upregulated DEGs were closely associated with the 'protein binding' and 'nucleic acid binding' terms, whereas the downregulated DEGs were closely associated with the 'protein binding' and 'ion binding' terms.

In addition, the top 10 enriched KEGG pathway terms of the up- and downregulated genes are provided in [Tables IV](#tIV-ol-0-0-11470){ref-type="table"} and [V](#tV-ol-0-0-11470){ref-type="table"}, respectively. The upregulated DEGs were primarily associated with the 'cell cycle', whereas the downregulated DEGs were primarily associated with the 'metabolic pathways'.

Notably, there were six genes with log~2~-fold change \>2 in DEGs enriched in the 'cell cycle' pathway: *SFN, BUB1B, TTK, CCNB1, CDK1* and *CDC20*. Differential expression analysis was performed on the aforementioned six genes in non-HBV tissues from two independent HCC datasets (TCGA and GSE76427) on different platforms (TCGA, Illumina RNA Sequencing; GSE76427, Illumina HumanHT-12 V4.0 expression beadchip). None of these genes had a log~2~-fold change \>2 ([Table VI](#tVI-ol-0-0-11470){ref-type="table"}), which demonstrates that the high expression of these six DEGs in HBV-associated HCC is more significant compared with non-HBV HCC.

### PPI network analysis of the DEGs

To further understand the biological meaning of the DEGs identified by the top KEGG pathways at the protein level, two PPI networks for the proteins encoded by the DEGs in the top pathways were constructed. The PPI network of the 'cell cycle' consisted of 24 nodes and 85 edges, whereas the PPI network of the 'metabolic pathways' consisted of 184 nodes and 566 edges ([Fig. 5](#f5-ol-0-0-11470){ref-type="fig"}).

Discussion
==========

The present study specifically focused on HBV-infected patients, which is different from the previous studies on HCC regardless of etiology ([@b19-ol-0-0-11470],[@b27-ol-0-0-11470]). A total of 682 upregulated DEGs and 1,252 downregulated DEGs were identified in HCC tissues compared with nontumor hepatic tissues in 321 HBV-positive samples. KEGG analyses demonstrated that the upregulated DEGs were enriched in signaling pathways such as the cell cycle, p53 signaling pathway and extracellular matrix-receptor interaction. A previous study showed that HBV infection deregulates the cell cycle pathway ([@b28-ol-0-0-11470]). Notably, there were 6 genes with a log~2~-fold change \>2 among the DEGs enriched in the 'cell cycle' pathway: *SFN, BUB1B, TTK, CCNB1, CDK1* and *CDC20*.

SFN (14-3-3σ) protein is a member of the 14-3-3 superfamily ([@b29-ol-0-0-11470]). SFN has been found to play a key role in various vital regulatory processes, such as cell cycle regulation and signaling pathways ([@b30-ol-0-0-11470]). In a previous study, high expression of SFN was detected in HCC tissues but not in adjacent nontumor tissues, which indicated an association between SFN and HCC ([@b31-ol-0-0-11470]). In another study, SFN exhibited high diagnostic accuracy in the differentiation of HCC from nontumorous hepatocytes ([@b32-ol-0-0-11470]).

BUB1B (encoding BUBR1) is an important component in the SAC protein family, which has been found to be involved in several forms of human cancer, such as lung cancer and breast cancer ([@b33-ol-0-0-11470],[@b34-ol-0-0-11470]). However, the contradiction of BUB1B expression in cancer cells remains controversial. Low expression of BUB1B is associated with the poor survival of patients with colon adenocarcinomas and lung cancer, however overexpression of BUB1B contributes to the progression and recurrence of gastric cancer and bladder cancer ([@b35-ol-0-0-11470]). However, several studies showed that the overexpression of BUB1B is associated with worse prognosis in patients with HCC ([@b36-ol-0-0-11470],[@b37-ol-0-0-11470]).

TTK, a dual-specific protein kinase participating in the p53 pathway, has been found to be involved in several cancer types by modulating the mitotic checkpoint ([@b38-ol-0-0-11470]). A previous study by Miao *et al* ([@b39-ol-0-0-11470]), regarding HBV-associated HCC, reported TTK as a promising prognostic marker of HCC. TTK alone can accurately predict the recurrence rate and recurrence time. These findings on TTK drew interest and resulted in further studies on cancer ([@b40-ol-0-0-11470]--[@b42-ol-0-0-11470]). The results of the present study supported the conclusion of the study by Miao *et al* ([@b39-ol-0-0-11470]).

CCNB1 plays an integral role in regulating the G~2~/M transition in the cell cycle ([@b43-ol-0-0-11470]). Several studies have found an elevated expression of CCNB1 in different cancer types, such as breast cancer ([@b44-ol-0-0-11470]), non-small cell carcinoma ([@b45-ol-0-0-11470]) and gastric cancer ([@b46-ol-0-0-11470]). In a previous study, CCNB1 was reported as an independent risk factor of recurrence in patients with HBV-associated HCC following surgery ([@b47-ol-0-0-11470]). However, it is still unclear how CCNB1 contributes to oncogenesis and tumor progression.

CDK1 is required for the role of CCNB1 in the G~2~/M transition and mitosis resumption ([@b48-ol-0-0-11470]). Cheng *et al* ([@b49-ol-0-0-11470]) conducted *in vitro* experiments, which demonstrated that HBV could activate the CCNB1-CDK1 kinase in HCC cells. In other studies, CCNB1 and CDK1 were found to be upregulated in the HCC tissues of HBV-positive patients ([@b50-ol-0-0-11470]). Moreover, overexpression of these two genes is associated with poor prognosis. CDK1 was considered important as CCNB1, since it could affect both overall survival and recurrence-free survival of HBV-positive patients with HCC ([@b51-ol-0-0-11470]).

CDC20 functions as a regulatory protein that interacts with several other proteins at multiple points in the cell cycle. Chae *et al* ([@b52-ol-0-0-11470]) demonstrated that HBV-infection could attenuate the association between BubR1 and CDC20, thus preventing CDC20 from performing its original function, which provided a novel view on the development of HBV-associated HCC.

The high expression of the six DEGs was more significant in HBV-associated HCC than in non-HBV HCC, and was validated in two independent HCC datasets. In future studies, clinical HCC samples should be collected in order to verify that these genes are affected by HBV infection.

The downregulated DEGs were enriched in signaling pathways such as 'carbon metabolism', 'glycine, serine and threonine metabolism', 'tryptophan metabolism', 'retinol metabolism' and 'alanine, aspartate and glutamate metabolism'. A previous study reported that HBV-infection could induce alterations in metabolic signaling pathways. The consequences may alter normal hepatocyte metabolism, thus contributing to the progression of HBV-associated carcinogenesis ([@b53-ol-0-0-11470]).

In conclusion, the present study identified several DEGs in HCC tissues compared with nontumor tissues from HBV-infected patients, based on a large cohort. Based on the DEGs, several key pathways were identified. The interactions of the DEGs in the pathways were also presented by PPI networks. Some results were consistent with previous studies ([@b39-ol-0-0-11470],[@b50-ol-0-0-11470]). Furthermore, the present study provides new insights into the specific etiology of HCC and molecular mechanisms for the transformation of nontumor hepatic tissues into HCC tissues, in patients with a history of HBV infection. Importantly, these results may provide several potential therapeutic targets for targeted therapy in these patients, which could aid early diagnosis and treatment of HCC.
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###### 

Characteristics of the datasets used in this study.

             Samples (n)                              
  ---------- ------------- ----- -------------------- ---------------------------------------------
  GSE17548   10            11    HBV hepatic tissue   Affymetrix Human Genome U133 Plus 2.0 Array
  GSE55092   49            91    HBV hepatic tissue   Affymetrix Human Genome U133 Plus 2.0 Array
  GSE62232   10            0     HBV hepatic tissue   Affymetrix Human Genome U133 Plus 2.0 Array
  GSE84044   0             124   HBV hepatic tissue   Affymetrix Human Genome U133 Plus 2.0 Array
  GSE84402   13            13    HBV hepatic tissue   Affymetrix Human Genome U133 Plus 2.0 Array

HCC, human hepatocellular carcinoma; HBV, hepatitis B virus.

###### 

Top 50 upregulated differentially expressed genes.

  Probe ID       Gene       Fold change   Adjusted P-value
  -------------- ---------- ------------- ------------------
  206239_s\_at   SPINK1     4.567348387   9.90×10^−43^
  211470_s\_at   SULT1C2    3.963534914   1.47×10^−64^
  205815_at      REG3A      3.770039412   1.10×10^−24^
  209220_at      GPC3       3.752196862   1.99×10^−40^
  201291_s\_at   TOP2A      3.555152759   3.85×10^−77^
  206561_s\_at   AKR1B10    3.468810343   1.21×10^−24^
  242881_x\_at   DUXAP10    3.301086607   1.01×10^−75^
  204602_at      DKK1       3.048004476   1.88×10^−37^
  203820_s\_at   IGF2BP3    3.043781559   1.76×10^−56^
  238021_s\_at   CRNDE      2.985078406   4.63×10^−52^
  209921_at      SLC7A11    2.980302339   1.66×10^−51^
  213194_at      ROBO1      2.947155321   1.69×10^−71^
  241418_at      NMRAL1P1   2.911349891   8.91×10^−59^
  223642_at      ZIC2       2.821525207   4.36×10^−64^
  222608_s\_at   ANLN       2.787055993   6.53×10^−62^
  209875_s\_at   SPP1       2.758625836   3.14×10^−23^
  235004_at      RBM24      2.743050577   1.06×10^−57^
  212551_at      CAP2       2.739651435   9.30×10^−91^
  214612_x\_at   MAGEA6     2.698311238   6.80×10^−34^
  202422_s\_at   ACSL4      2.663914238   2.38×10^−33^
  219918_s\_at   ASPM       2.652302575   4.07×10^−52^
  235763_at      SLC44A5    2.472658451   2.37×10^−33^
  207828_s\_at   CENPF      2.472581020   2.98×10^−78^
  214710_s\_at   CCNB1      2.403923370   1.64×10^−56^
  225681_at      CTHRC1     2.384346752   1.53×10^−25^
  212531_at      LCN2       2.383664937   3.04×10^−31^
  201890_at      RRM2       2.381259393   3.31×10^−38^
  33323_r\_at    SFN        2.365919617   9.97×10^−36^
  218009_s\_at   PRC1       2.350952594   8.64×10^−54^
  204162_at      NDC80      2.332439517   1.54×10^−54^
  219787_s\_at   ECT2       2.313749179   8.57×10^−52^
  207165_at      HMMR       2.304640216   1.82×10^−48^
  204825_at      MELK       2.298883197   1.43×10^−57^
  203477_at      COL15A1    2.295323078   1.49×10^−33^
  203213_at      CDK1       2.271576100   9.42×10^−49^
  206626_x\_at   SSX1       2.253448717   3.68×10^−30^
  207325_x\_at   MAGEA1     2.252155461   3.97×10^−42^
  204720_s\_at   DNAJC6     2.236082454   2.40×10^−52^
  204105_s\_at   NRCAM      2.232778933   1.57×10^−38^
  227892_at      PRKAA2     2.229124796   3.47×10^−44^
  227510_x\_at   MALAT1     2.224576694   5.41×10^−17^
  201468_s\_at   NQO1       2.209490964   2.70×10^−26^
  205110_s\_at   FGF13      2.207535230   1.23×10^−32^
  223381_at      NUF2       2.186987390   5.66×10^−56^
  205476_at      CCL20      2.181812965   1.34×10^−20^
  203755_at      BUB1B      2.178984131   2.76×10^−50^
  218755_at      KIF20A     2.153373571   8.72×10^−52^
  231265_at      COX7B2     2.150792051   5.69×10^−41^
  221558_s\_at   LEF1       2.122850025   2.29×10^−38^
  225612_s\_at   B3GNT5     2.117997087   7.16×10^−31^

###### 

Top 50 downregulated differentially expressed genes.

  Probe ID        Gene        Fold change    Adjusted P-value
  --------------- ----------- -------------- ------------------
  220491_at       HAMP        −4.983632921   4.89×10^−60^
  205866_at       FCN3        −4.729403108   1.63×10^−96^
  222484_s\_at    CXCL14      −4.664513026   2.76×10^−105^
  205984_at       CRHBP       −4.504769969   5.41×10^−83^
  207804_s\_at    FCN2        −4.498217224   1.69×10^−97^
  207201_s\_at    SLC22A1     −4.496482306   9.93×10^−68^
  220496_at       CLEC1B      −4.489579549   1.13×10^−112^
  217546_at       MT1M        −4.427062929   4.20×10^−64^
  230478_at       OIT3        −4.401727477   1.29×10^−106^
  1559573_at      LINC01093   −4.372165201   7.87×10^−89^
  223699_at       CNDP1       −4.185131569   2.30×10^−73^
  229476_s\_at    THRSP       −4.124366630   2.88×10^−56^
  1559065_a\_at   CLEC4G      −4.114961753   1.36×10^−99^
  206354_at       SLCO1B3     −4.081557901   3.55×10^−63^
  207102_at       AKR1D1      −4.020716573   6.22×10^−69^
  1564706_s\_at   GLS2        −4.018224948   3.74×10^−70^
  207608_x\_at    CYP1A2      −4.013090089   7.43×10^−78^
  206727_at       C9          −3.961247256   9.82×10^−48^
  209687_at       CXCL12      −3.885309405   1.16×10^−60^
  219014_at       PLAC8       −3.774128748   3.42×10^−72^
  207995_s\_at    CLEC4M      −3.732362194   5.50×10^−88^
  231678_s\_at    ADH4        −3.682472263   1.77×10^−48^
  205554_s\_at    DNASE1L3    −3.666231016   1.29×10^−68^
  220801_s\_at    HAO2        −3.663835833   4.99×10^−76^
  211896_s\_at    DCN         −3.625520940   1.19×10^−46^
  220432_s\_at    CYP39A1     −3.616388369   2.51×10^−64^
  220116_at       KCNN2       −3.587327181   4.31×10^−57^
  205819_at       MARCO       −3.569710716   5.45×10^−76^
  202992_at       C7          −3.473352727   3.89×10^−43^
  230135_at       HHIP        −3.458281369   1.29×10^−91^
  210328_at       GNMT        −3.412414732   1.25×10^−52^
  213629_x\_at    MT1F        −3.412271922   3.79×10^−72^
  214478_at       SPP2        −3.405396399   1.74×10^−74^
  205225_at       ESR1        −3.355285624   2.09×10^−74^
  237350_at       TTC36       −3.334397580   7.78×10^−84^
  214320_x\_at    CYP2A6      −3.332114585   3.55×10^−54^
  219954_s\_at    GBA3        −3.304920162   1.98×10^−59^
  207262_at       APOF        −3.287687923   1.09×10^−72^
  214621_at       GYS2        −3.272101039   8.61×10^−56^
  206797_at       NAT2        −3.270355860   8.59×10^−76^
  242817_at       PGLYRP2     −3.225627679   2.41×10^−53^
  205498_at       GHR         −3.223775643   1.20×10^−66^
  237390_at       ADRA1A      −3.213027372   8.85×10^−54^
  204704_s\_at    ALDOB       −3.208187451   3.84×10^−55^
  209301_at       CA2         −3.203130234   1.38×10^−58^
  206172_at       IL13RA2     −3.185151095   1.11×10^−52^
  206210_s\_at    CETP        −3.179352566   1.73×10^−66^
  204428_s\_at    LCAT        −3.145019681   1.47×10^−76^
  205363_at       BBOX1       −3.135951206   2.16×10^−42^
  208147_s\_at    CYP2C8      −3.115222728   8.68×10^−61^

###### 

Top 10 enriched KEGG pathway terms of upregulated differentially expressed genes.

  KEGG ID    KEGG pathway                   No. ofss genes   P-value
  ---------- ------------------------------ ---------------- --------------
  hsa04110   Cell cycle                     24               2.51×10^−14^
  hsa05222   Small cell lung cancer         13               5.70×10^−07^
  hsa05200   Pathways in cancer             28               4.02×10^−06^
  hsa04512   ECM-receptor interaction       11               1.42×10^−05^
  hsa04115   p53 signaling pathway          10               1.76×10^−05^
  hsa04151   PI3K-Akt signaling pathwayss   21               4.69×10^−04^
  hsa04510   Focal adhesion                 15               4.89×10^−04^
  hsa05146   Amoebiasis                     9                1.74×10^−03^
  hsa05213   Endometrial cancer             6                2.97×10^−03^
  hsa05218   Melanoma                       7                3.37×10^−03^

KEGG, Kyoto Encyclopedia of Genes and Genomes; ECM, extracellular matrix.

###### 

Top 10 enriched KEGG pathway terms of downregulated differentially expressed genes.

  KEGG ID    KEGG pathway                                  No. of genes   P-value
  ---------- --------------------------------------------- -------------- --------------
  hsa01100   Metabolic pathways                            185            \<0.01
  hsa04610   Complement and coagulation cascades           33             \<0.01
  hsa05204   Chemical carcinogenesis                       27             5.49×10^−12^
  hsa01200   Carbon metabolism                             30             2.04×10^−10^
  hsa00260   Glycine, serine and threonine metabolism      17             5.18×10^−10^
  hsa00380   Tryptophan metabolism                         17             5.18×10^−10^
  hsa05150   Staphylococcus aureus infection               20             6.30×10^−10^
  hsa00830   Retinol metabolism                            21             1.95×10^−09^
  hsa00071   Fatty acid degradation                        17             3.05×10^−09^
  hsa00250   Alanine, aspartate and glutamate metabolism   15             4.8×10^−09^

KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Differential expression of six differentially expressed genes in different datasets.

          Large HBV cohort   GSE76427       TCGA                                 
  ------- ------------------ -------------- ---------- -------------- ---------- --------------
  CCNB1   2.403923           1.64×10^−56^   0.587062   1.36×10^−11^   0.607121   1.92×10^−11^
  SFN     2.365920           9.97×10^−36^   0.880437   3.36×10^−03^   0.676444   2.14×10^−05^
  CDK1    2.271576           9.42×10^−49^   0.802341   5.35×10^−11^   0.769405   1.93×10^−11^
  BUB1B   2.178984           2.76×10^−50^   1.121998   5.27×10^−12^   0.234839   9.11×10^−07^
  TTK     2.066772           2.45×10^−47^   1.587680   3.34×10^−13^   0.791737   2.17×10^−12^
  CDC20   2.012448           7.80×10^−46^   1.073711   8.29×10^−09^   1.712167   4.21×10^−10^

HBV, hepatitis B virus; Adj., adjusted; TCGA, The Cancer Genome Atlas.

[^1]: Contributed equally
